NEW DELHI, Dec. 9, 2025 /PRNewswire/ -- Miltenyi Biotec has been honoured with the Special Recognition Award for Pioneering Work…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was awarded silver by EcoVadis. This year, the company has…
Hyundai Motor Group signs a multilateral MoU with Pyeongtaek City and key stakeholders to develop carbon-neutral hydrogen port initiativesKia and…
KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have entered a Strategic Cooperation Agreement for Joint Market…
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic…
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered…
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…